Evaluation of Male Breast Cancer and the Application of Sentinel Lymph Node Biopsy: A Multicenter Retrospective Study
Sentinel lymph node biopsy (SLNB) is currently used as a routine treatment for patients with breast cancer. However, it may not be applicable for patients with male breast cancer (MBC), because they have notably different clinicopathological features from those occurring in females. There is a lack...
Gespeichert in:
| Veröffentlicht in: | The oncologist (Dayton, Ohio) Ohio), 2023-12, Vol.28 (12), p.e1170-e1178 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e1178 |
|---|---|
| container_issue | 12 |
| container_start_page | e1170 |
| container_title | The oncologist (Dayton, Ohio) |
| container_volume | 28 |
| creator | Shang, Qingyao Feng, Kexin Wei, Ya Wang, Kaipeng Yang, Chenxuan Zhao, Shuangtao Liu, Jiaxiang Meng, Xiangzhi Li, Yalun Du, Chuang Wang, Jing Qiao, Guangdong Li, Jingruo Wang, Xin Wang, Xiang |
| description | Sentinel lymph node biopsy (SLNB) is currently used as a routine treatment for patients with breast cancer. However, it may not be applicable for patients with male breast cancer (MBC), because they have notably different clinicopathological features from those occurring in females. There is a lack of evidence of SLNB application and safe exemption from axillary lymph node dissection (ALND) in patients with MBC. This study aimed to evaluate the application of SLNB to provide information for the standardized treatment of patients with MBC. The MBC patient records from 4 institutions ranging from January 2001 to November 2020 were retrospectively reviewed. There were 220 patients with MBC with a median age of 60 (range 24-88) years and an average tumor size of 2.3 cm (range 0.5 cm-6.5 cm). Sixty-six percent of patients underwent SLNB, and 39% of them showed positive results. A total of 157 patients underwent ALND, while only half of them had positive nodes, causing unnecessary complications. For patients in the clinical early stage, we found that the SLNB showed a noninferiority to the ALND treatment in DFS (P = .18) and OS (P = .055). In conclusion, there are certain obstacles to the broad application of SLNB due to the lower proportion of patients with clinically negative lymph nodes. However, it is undeniable that SLNB can safely and effectively exempt patients with MBC at early stage with clinically negative nodes from ALND to reduce subsequent complications. It is still an ideal criterion for the axillary staging of patients with MBC.
Sentinel lymph node biopsy (SLNB) is used as a routine treatment for patients with breast cancer; however, it may not be useful for male patients because of the differences in clinicopathological features of male versus female patients. This study evaluated the application of SLNB to provide information for the standardized treatment of patients with metastatic breast cancer. |
| doi_str_mv | 10.1093/oncolo/oyad189 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10712710</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A781010894</galeid><oup_id>10.1093/oncolo/oyad189</oup_id><sourcerecordid>A781010894</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-e9d5a77bba60f25f43573f985ac08994051ee3a76107cd8234a26e9c6227dac93</originalsourceid><addsrcrecordid>eNqFkkuLFDEQgIMo7rp69SgBL3ro3Ty6Jx0vMg7rA2YVXAVvIZNU70TSSdtJD_S_N8OMg8KC5JCQfPVRqSqEnlNySYnkVzGY6ONVnLWlrXyAzmlTy6qW5MfDciYtrwRt5Bl6ktJPQsqRs8fojAsuJWPtOZqud9pPOrsYcOzwjfaA342gU8YrHQyMWAeL8xbwchi8MyfyFkJ2ATxez_2wxZ-jLYEuDml-g5f4ZvLZmYIUwVfIY0wDmOx2gG_zZOen6FGnfYJnx_0CfX9__W31sVp_-fBptVxXppYsVyBto4XYbPSCdKzpat4I3sm20Ya0UtakoQBciwUlwtiW8VqzBUizYExYbSS_QG8P3mHa9GD3CY3aq2F0vR5nFbVT_74Et1V3caeKkDJBSTG8OhrG-GuClFXvkgHvdYA4JcVazgnjpGYFfXlA70oRlQtdLEqzx9VStJSUbsi6UJf3UGVZ6J2JATpX7u8LMKWKaYTulD4laj8D6jAD6jgDJeDF358-4X-aXoDXByBOw_9kvwE89r5T</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2833023042</pqid></control><display><type>article</type><title>Evaluation of Male Breast Cancer and the Application of Sentinel Lymph Node Biopsy: A Multicenter Retrospective Study</title><source>Oxford Journals Open Access Collection</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Shang, Qingyao ; Feng, Kexin ; Wei, Ya ; Wang, Kaipeng ; Yang, Chenxuan ; Zhao, Shuangtao ; Liu, Jiaxiang ; Meng, Xiangzhi ; Li, Yalun ; Du, Chuang ; Wang, Jing ; Qiao, Guangdong ; Li, Jingruo ; Wang, Xin ; Wang, Xiang</creator><creatorcontrib>Shang, Qingyao ; Feng, Kexin ; Wei, Ya ; Wang, Kaipeng ; Yang, Chenxuan ; Zhao, Shuangtao ; Liu, Jiaxiang ; Meng, Xiangzhi ; Li, Yalun ; Du, Chuang ; Wang, Jing ; Qiao, Guangdong ; Li, Jingruo ; Wang, Xin ; Wang, Xiang</creatorcontrib><description>Sentinel lymph node biopsy (SLNB) is currently used as a routine treatment for patients with breast cancer. However, it may not be applicable for patients with male breast cancer (MBC), because they have notably different clinicopathological features from those occurring in females. There is a lack of evidence of SLNB application and safe exemption from axillary lymph node dissection (ALND) in patients with MBC. This study aimed to evaluate the application of SLNB to provide information for the standardized treatment of patients with MBC. The MBC patient records from 4 institutions ranging from January 2001 to November 2020 were retrospectively reviewed. There were 220 patients with MBC with a median age of 60 (range 24-88) years and an average tumor size of 2.3 cm (range 0.5 cm-6.5 cm). Sixty-six percent of patients underwent SLNB, and 39% of them showed positive results. A total of 157 patients underwent ALND, while only half of them had positive nodes, causing unnecessary complications. For patients in the clinical early stage, we found that the SLNB showed a noninferiority to the ALND treatment in DFS (P = .18) and OS (P = .055). In conclusion, there are certain obstacles to the broad application of SLNB due to the lower proportion of patients with clinically negative lymph nodes. However, it is undeniable that SLNB can safely and effectively exempt patients with MBC at early stage with clinically negative nodes from ALND to reduce subsequent complications. It is still an ideal criterion for the axillary staging of patients with MBC.
Sentinel lymph node biopsy (SLNB) is used as a routine treatment for patients with breast cancer; however, it may not be useful for male patients because of the differences in clinicopathological features of male versus female patients. This study evaluated the application of SLNB to provide information for the standardized treatment of patients with metastatic breast cancer.</description><identifier>ISSN: 1083-7159</identifier><identifier>EISSN: 1549-490X</identifier><identifier>DOI: 10.1093/oncolo/oyad189</identifier><identifier>PMID: 37399228</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Axilla - pathology ; Biopsy ; Breast Cancer ; Breast Neoplasms - pathology ; Breast Neoplasms, Male - pathology ; Breast Neoplasms, Male - surgery ; Care and treatment ; Diagnosis ; Female ; Humans ; Lymph Node Excision - methods ; Lymph nodes ; Lymph Nodes - pathology ; Lymph Nodes - surgery ; Lymphatic Metastasis - pathology ; Male ; Male breast cancer ; Middle Aged ; Practice guidelines (Medicine) ; Prognosis ; Retrospective Studies ; Sentinel Lymph Node - pathology ; Sentinel Lymph Node - surgery ; Sentinel Lymph Node Biopsy - methods ; Young Adult</subject><ispartof>The oncologist (Dayton, Ohio), 2023-12, Vol.28 (12), p.e1170-e1178</ispartof><rights>The Author(s) 2023. Published by Oxford University Press. 2023</rights><rights>The Author(s) 2023. Published by Oxford University Press.</rights><rights>COPYRIGHT 2023 Oxford University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c492t-e9d5a77bba60f25f43573f985ac08994051ee3a76107cd8234a26e9c6227dac93</citedby><cites>FETCH-LOGICAL-c492t-e9d5a77bba60f25f43573f985ac08994051ee3a76107cd8234a26e9c6227dac93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10712710/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10712710/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1598,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37399228$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shang, Qingyao</creatorcontrib><creatorcontrib>Feng, Kexin</creatorcontrib><creatorcontrib>Wei, Ya</creatorcontrib><creatorcontrib>Wang, Kaipeng</creatorcontrib><creatorcontrib>Yang, Chenxuan</creatorcontrib><creatorcontrib>Zhao, Shuangtao</creatorcontrib><creatorcontrib>Liu, Jiaxiang</creatorcontrib><creatorcontrib>Meng, Xiangzhi</creatorcontrib><creatorcontrib>Li, Yalun</creatorcontrib><creatorcontrib>Du, Chuang</creatorcontrib><creatorcontrib>Wang, Jing</creatorcontrib><creatorcontrib>Qiao, Guangdong</creatorcontrib><creatorcontrib>Li, Jingruo</creatorcontrib><creatorcontrib>Wang, Xin</creatorcontrib><creatorcontrib>Wang, Xiang</creatorcontrib><title>Evaluation of Male Breast Cancer and the Application of Sentinel Lymph Node Biopsy: A Multicenter Retrospective Study</title><title>The oncologist (Dayton, Ohio)</title><addtitle>Oncologist</addtitle><description>Sentinel lymph node biopsy (SLNB) is currently used as a routine treatment for patients with breast cancer. However, it may not be applicable for patients with male breast cancer (MBC), because they have notably different clinicopathological features from those occurring in females. There is a lack of evidence of SLNB application and safe exemption from axillary lymph node dissection (ALND) in patients with MBC. This study aimed to evaluate the application of SLNB to provide information for the standardized treatment of patients with MBC. The MBC patient records from 4 institutions ranging from January 2001 to November 2020 were retrospectively reviewed. There were 220 patients with MBC with a median age of 60 (range 24-88) years and an average tumor size of 2.3 cm (range 0.5 cm-6.5 cm). Sixty-six percent of patients underwent SLNB, and 39% of them showed positive results. A total of 157 patients underwent ALND, while only half of them had positive nodes, causing unnecessary complications. For patients in the clinical early stage, we found that the SLNB showed a noninferiority to the ALND treatment in DFS (P = .18) and OS (P = .055). In conclusion, there are certain obstacles to the broad application of SLNB due to the lower proportion of patients with clinically negative lymph nodes. However, it is undeniable that SLNB can safely and effectively exempt patients with MBC at early stage with clinically negative nodes from ALND to reduce subsequent complications. It is still an ideal criterion for the axillary staging of patients with MBC.
Sentinel lymph node biopsy (SLNB) is used as a routine treatment for patients with breast cancer; however, it may not be useful for male patients because of the differences in clinicopathological features of male versus female patients. This study evaluated the application of SLNB to provide information for the standardized treatment of patients with metastatic breast cancer.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Axilla - pathology</subject><subject>Biopsy</subject><subject>Breast Cancer</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms, Male - pathology</subject><subject>Breast Neoplasms, Male - surgery</subject><subject>Care and treatment</subject><subject>Diagnosis</subject><subject>Female</subject><subject>Humans</subject><subject>Lymph Node Excision - methods</subject><subject>Lymph nodes</subject><subject>Lymph Nodes - pathology</subject><subject>Lymph Nodes - surgery</subject><subject>Lymphatic Metastasis - pathology</subject><subject>Male</subject><subject>Male breast cancer</subject><subject>Middle Aged</subject><subject>Practice guidelines (Medicine)</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Sentinel Lymph Node - pathology</subject><subject>Sentinel Lymph Node - surgery</subject><subject>Sentinel Lymph Node Biopsy - methods</subject><subject>Young Adult</subject><issn>1083-7159</issn><issn>1549-490X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><sourceid>EIF</sourceid><recordid>eNqFkkuLFDEQgIMo7rp69SgBL3ro3Ty6Jx0vMg7rA2YVXAVvIZNU70TSSdtJD_S_N8OMg8KC5JCQfPVRqSqEnlNySYnkVzGY6ONVnLWlrXyAzmlTy6qW5MfDciYtrwRt5Bl6ktJPQsqRs8fojAsuJWPtOZqud9pPOrsYcOzwjfaA342gU8YrHQyMWAeL8xbwchi8MyfyFkJ2ATxez_2wxZ-jLYEuDml-g5f4ZvLZmYIUwVfIY0wDmOx2gG_zZOen6FGnfYJnx_0CfX9__W31sVp_-fBptVxXppYsVyBto4XYbPSCdKzpat4I3sm20Ya0UtakoQBciwUlwtiW8VqzBUizYExYbSS_QG8P3mHa9GD3CY3aq2F0vR5nFbVT_74Et1V3caeKkDJBSTG8OhrG-GuClFXvkgHvdYA4JcVazgnjpGYFfXlA70oRlQtdLEqzx9VStJSUbsi6UJf3UGVZ6J2JATpX7u8LMKWKaYTulD4laj8D6jAD6jgDJeDF358-4X-aXoDXByBOw_9kvwE89r5T</recordid><startdate>20231211</startdate><enddate>20231211</enddate><creator>Shang, Qingyao</creator><creator>Feng, Kexin</creator><creator>Wei, Ya</creator><creator>Wang, Kaipeng</creator><creator>Yang, Chenxuan</creator><creator>Zhao, Shuangtao</creator><creator>Liu, Jiaxiang</creator><creator>Meng, Xiangzhi</creator><creator>Li, Yalun</creator><creator>Du, Chuang</creator><creator>Wang, Jing</creator><creator>Qiao, Guangdong</creator><creator>Li, Jingruo</creator><creator>Wang, Xin</creator><creator>Wang, Xiang</creator><general>Oxford University Press</general><scope>TOX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20231211</creationdate><title>Evaluation of Male Breast Cancer and the Application of Sentinel Lymph Node Biopsy: A Multicenter Retrospective Study</title><author>Shang, Qingyao ; Feng, Kexin ; Wei, Ya ; Wang, Kaipeng ; Yang, Chenxuan ; Zhao, Shuangtao ; Liu, Jiaxiang ; Meng, Xiangzhi ; Li, Yalun ; Du, Chuang ; Wang, Jing ; Qiao, Guangdong ; Li, Jingruo ; Wang, Xin ; Wang, Xiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-e9d5a77bba60f25f43573f985ac08994051ee3a76107cd8234a26e9c6227dac93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Axilla - pathology</topic><topic>Biopsy</topic><topic>Breast Cancer</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms, Male - pathology</topic><topic>Breast Neoplasms, Male - surgery</topic><topic>Care and treatment</topic><topic>Diagnosis</topic><topic>Female</topic><topic>Humans</topic><topic>Lymph Node Excision - methods</topic><topic>Lymph nodes</topic><topic>Lymph Nodes - pathology</topic><topic>Lymph Nodes - surgery</topic><topic>Lymphatic Metastasis - pathology</topic><topic>Male</topic><topic>Male breast cancer</topic><topic>Middle Aged</topic><topic>Practice guidelines (Medicine)</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Sentinel Lymph Node - pathology</topic><topic>Sentinel Lymph Node - surgery</topic><topic>Sentinel Lymph Node Biopsy - methods</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shang, Qingyao</creatorcontrib><creatorcontrib>Feng, Kexin</creatorcontrib><creatorcontrib>Wei, Ya</creatorcontrib><creatorcontrib>Wang, Kaipeng</creatorcontrib><creatorcontrib>Yang, Chenxuan</creatorcontrib><creatorcontrib>Zhao, Shuangtao</creatorcontrib><creatorcontrib>Liu, Jiaxiang</creatorcontrib><creatorcontrib>Meng, Xiangzhi</creatorcontrib><creatorcontrib>Li, Yalun</creatorcontrib><creatorcontrib>Du, Chuang</creatorcontrib><creatorcontrib>Wang, Jing</creatorcontrib><creatorcontrib>Qiao, Guangdong</creatorcontrib><creatorcontrib>Li, Jingruo</creatorcontrib><creatorcontrib>Wang, Xin</creatorcontrib><creatorcontrib>Wang, Xiang</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The oncologist (Dayton, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shang, Qingyao</au><au>Feng, Kexin</au><au>Wei, Ya</au><au>Wang, Kaipeng</au><au>Yang, Chenxuan</au><au>Zhao, Shuangtao</au><au>Liu, Jiaxiang</au><au>Meng, Xiangzhi</au><au>Li, Yalun</au><au>Du, Chuang</au><au>Wang, Jing</au><au>Qiao, Guangdong</au><au>Li, Jingruo</au><au>Wang, Xin</au><au>Wang, Xiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of Male Breast Cancer and the Application of Sentinel Lymph Node Biopsy: A Multicenter Retrospective Study</atitle><jtitle>The oncologist (Dayton, Ohio)</jtitle><addtitle>Oncologist</addtitle><date>2023-12-11</date><risdate>2023</risdate><volume>28</volume><issue>12</issue><spage>e1170</spage><epage>e1178</epage><pages>e1170-e1178</pages><issn>1083-7159</issn><eissn>1549-490X</eissn><abstract>Sentinel lymph node biopsy (SLNB) is currently used as a routine treatment for patients with breast cancer. However, it may not be applicable for patients with male breast cancer (MBC), because they have notably different clinicopathological features from those occurring in females. There is a lack of evidence of SLNB application and safe exemption from axillary lymph node dissection (ALND) in patients with MBC. This study aimed to evaluate the application of SLNB to provide information for the standardized treatment of patients with MBC. The MBC patient records from 4 institutions ranging from January 2001 to November 2020 were retrospectively reviewed. There were 220 patients with MBC with a median age of 60 (range 24-88) years and an average tumor size of 2.3 cm (range 0.5 cm-6.5 cm). Sixty-six percent of patients underwent SLNB, and 39% of them showed positive results. A total of 157 patients underwent ALND, while only half of them had positive nodes, causing unnecessary complications. For patients in the clinical early stage, we found that the SLNB showed a noninferiority to the ALND treatment in DFS (P = .18) and OS (P = .055). In conclusion, there are certain obstacles to the broad application of SLNB due to the lower proportion of patients with clinically negative lymph nodes. However, it is undeniable that SLNB can safely and effectively exempt patients with MBC at early stage with clinically negative nodes from ALND to reduce subsequent complications. It is still an ideal criterion for the axillary staging of patients with MBC.
Sentinel lymph node biopsy (SLNB) is used as a routine treatment for patients with breast cancer; however, it may not be useful for male patients because of the differences in clinicopathological features of male versus female patients. This study evaluated the application of SLNB to provide information for the standardized treatment of patients with metastatic breast cancer.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>37399228</pmid><doi>10.1093/oncolo/oyad189</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-7159 |
| ispartof | The oncologist (Dayton, Ohio), 2023-12, Vol.28 (12), p.e1170-e1178 |
| issn | 1083-7159 1549-490X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10712710 |
| source | Oxford Journals Open Access Collection; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adult Aged Aged, 80 and over Axilla - pathology Biopsy Breast Cancer Breast Neoplasms - pathology Breast Neoplasms, Male - pathology Breast Neoplasms, Male - surgery Care and treatment Diagnosis Female Humans Lymph Node Excision - methods Lymph nodes Lymph Nodes - pathology Lymph Nodes - surgery Lymphatic Metastasis - pathology Male Male breast cancer Middle Aged Practice guidelines (Medicine) Prognosis Retrospective Studies Sentinel Lymph Node - pathology Sentinel Lymph Node - surgery Sentinel Lymph Node Biopsy - methods Young Adult |
| title | Evaluation of Male Breast Cancer and the Application of Sentinel Lymph Node Biopsy: A Multicenter Retrospective Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T13%3A13%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20Male%20Breast%20Cancer%20and%20the%20Application%20of%20Sentinel%20Lymph%20Node%20Biopsy:%20A%20Multicenter%20Retrospective%20Study&rft.jtitle=The%20oncologist%20(Dayton,%20Ohio)&rft.au=Shang,%20Qingyao&rft.date=2023-12-11&rft.volume=28&rft.issue=12&rft.spage=e1170&rft.epage=e1178&rft.pages=e1170-e1178&rft.issn=1083-7159&rft.eissn=1549-490X&rft_id=info:doi/10.1093/oncolo/oyad189&rft_dat=%3Cgale_pubme%3EA781010894%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2833023042&rft_id=info:pmid/37399228&rft_galeid=A781010894&rft_oup_id=10.1093/oncolo/oyad189&rfr_iscdi=true |